logo
Acceleware Announces RF XL 2.0

Acceleware Announces RF XL 2.0

CALGARY, Alberta, June 25, 2025 (GLOBE NEWSWIRE) — Acceleware® Ltd. ('Acceleware' or the 'Company') (TSX-V: AXE), a leading innovator of cutting-edge radio frequency ('RF') power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, is pleased to announce details of the next generation of RF XL, ('RF XL 2.0') and a new demonstration plan (the 'Demonstration').
'RF XL', Acceleware's enhanced oil recovery ('EOR') technology that uses RF heating to energize oil formations, is a major innovation that could potentially decarbonize heavy oil and oil sands production effectively and efficiently by materially lowering costs compared to other EOR techniques, increasing the recovery factor, and potentially stimulating investment.
The RF XL Marwayne deployment was supported by three major operators and progressed from
Technology Readiness Level
('TRL') 4 to TRL 8, with its core technology, the Clean Tech Inverter ('CTI') progressing to TRL 9. This deployment successfully demonstrated RF XL's potential by heating the reservoir and increasing temperatures in the production well while achieving the highest power level and longest continuous run time for any RF based EOR technology.
Buoyed by the initial results at Marwayne, and the promise of increased oil production with higher power, Acceleware was encouraged by funders and industry partners to upgrade and improve to next generation RF XL 2.0.
Key components of the RF XL 2.0 development process included:
Acceleware is currently seeking funding for the RF XL 2.0 Demonstration: a commercial-scale project that builds on work performed to date and could showcase RF XL's ability to enhance recovery in heavy oil reservoirs - particularly in the Lloydminster area - and increase production while decarbonizing. A previously announced non-dilutive grant in the amount of $1.31 million from the Clean Resource Innovation Network has been withdrawn due to timing constraints - eligible costs had to have been incurred between January 1, 2024, and September 30, 2025. However, multiple non-dilutive funding calls from both provincial and federal agencies are currently available and are being pursued.
Said Acceleware's CEO Geoff Clark, 'Combining the potential to economically produce more oil faster while decarbonizing is a compelling scenario for industry and governments alike. Once proven at commercial scale, RF XL 2.0 could serve to support Canada's ambition to lead as a G7 energy innovator and superpower. We have a bold strategy in place to progress the technology as quickly as possible - we are keen to show the world what RF XL 2.0 can do.'
About Acceleware:
Acceleware is an advanced electromagnetic heating company with cutting-edge RF power-to-heat solutions for large industrial applications. The Company's technologies provide an opportunity to electrify and decarbonize industrial process heat applications while reducing costs.
The Company is working to use its patented and field proven CTI to materially improve the efficiency of amine regeneration, and has partnered with a consortium of world-class potash partners seeking to decarbonize drying of potash ore and other critical minerals. Acceleware is actively developing other process heat applications and partnerships for RF heating.
Acceleware's RF XL is a patented low-cost, low-carbon RF thermal enhanced oil production technology for heavy oil that is materially different from any enhanced recovery technique used today.
Acceleware is a public company listed on the TSX Venture Exchange ('TSXV') under the trading symbol 'AXE'.
Cautionary Statements
This news release contains forward-looking statements and/or forward-looking information (collectively, 'forward-looking statements') within the meaning of applicable securities laws. When used in this release, such words as 'will', 'anticipates', 'believes', 'intends', 'expects', 'could' and similar expressions, as they relate to Acceleware, or its management, are intended to identify such forward-looking statements. Such forward-looking statements reflect the current views of Acceleware with respect to future events, and are subject to certain risks, uncertainties and assumptions. Many factors could cause Acceleware's actual results, performance or achievements to be materially different from any expected future results, performance or achievement that may be expressed or implied by such forward-looking statements. Certain information and statements contained in this news release constitute forward-looking statements, which reflects Acceleware's current expectations regarding future events, including, but not limited to: the potential benefits and commercialization of RF XL and CTI, the development and execution of a the Demonstration; the Company's ability to successfully execute the Demonstration; the expected benefits of the Demonstration; the ability of the Company to raise sufficient capital to execute the Demonstration; potential restructuring efforts of the Company's business lines; the potential acquisition by the Company of certain assets, deployment of RF XL
2.0; and related potential for multi-well expansion; the initiatives to be implemented by management to shift the Company's focus from research and development to cash flow generation; the receipt of applicable approvals (including board, shareholder, and approvals of the TSXV) to implement key components of the Demonstration; the timing to complete certain increments of the Demonstration; and the impact of the Demonstration on Acceleware's business and shareholder value.
Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the availability of potential heavy oil production rights in western Canada, the availability of investment capital and other funding, the high degree of uncertainties inherent to feasibility and economic studies which are based to a significant extent on various assumptions; variations in commodity prices and exchange rate fluctuations; variations in cost of supplies and labour; lack of availability of qualified personnel; receipt of necessary approvals; availability of financing for technology and project development; uncertainties and risks with respect to developing and adopting new technologies; general business, economic, competitive, political and social uncertainties; change in demand for technologies to be offered by the Company; obtaining required approvals of regulatory authorities and/or shareholders, as applicable; ability to access sufficient capital from internal and external sources. For a more fulsome list of risk factors please see the Company's December 31, 2024, year-end Management Discussion and Analysis available on SEDAR+ at
www.sedarplus.ca
.
Management of the Company has included the above summary of assumptions and risks related to forward-looking statements provided in this release to provide shareholders with a more complete perspective on the Company's current and future operations and such information may not be appropriate for other purposes. The Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements included in this news release should not be read as guarantees of future performance or results. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
For more information:
Geoff Clark
Tel: +1 (403) 249-9099
geoff.clark@acceleware.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Western Carriers shares surge 10% after company wins Rs 558 crore logistics contract from Jindal Stainless
Western Carriers shares surge 10% after company wins Rs 558 crore logistics contract from Jindal Stainless

Business Upturn

time30 minutes ago

  • Business Upturn

Western Carriers shares surge 10% after company wins Rs 558 crore logistics contract from Jindal Stainless

By Aman Shukla Published on June 26, 2025, 09:19 IST Western Carriers (India) Ltd (WCIL) shares jumped 10% in morning trade after the company announced a major logistics contract win worth ₹558 crore from Jindal Stainless Limited (JSL). As of 9:18 AM, the shares were trading 8.81% higher at Rs 119.70. The three-year agreement involves the transportation of slabs, coils, and sheet plates using DSO containers across multiple destinations in India. This development strengthens WCIL's ongoing relationship with JSL and reinforces its capability in handling complex and large-scale logistics operations in the metals and manufacturing sector. Commenting on the development, Rajendra Sethia, Chairman and Managing Director of WCIL, said, 'This prestigious mandate reinforces our capabilities in managing large-scale, mission-critical logistics operations across India. We remain committed to delivering efficient and quality services to support the domestic industrial ecosystem.' The deal positions Western Carriers as a key logistics partner for top-tier Indian corporations, underlining its strengths in scalability, reliability, and customer-centric operations. With this win, WCIL continues to expand its footprint in India's booming industrial supply chain sector. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Optiva Inc. Announces Results of Annual Meeting
Optiva Inc. Announces Results of Annual Meeting

Hamilton Spectator

time2 hours ago

  • Hamilton Spectator

Optiva Inc. Announces Results of Annual Meeting

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Optiva Inc. ('Optiva' or the 'Company') (TSX:OPT), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today announced that Patrick DiPietro, Lee Matheson, Simon Parmar, Robert Stabile, Barry Symons, and Birgit Troy were elected to the Company's board of directors (the 'Board') at the Company's annual meeting of holders of common shares held earlier today (the 'Meeting'). In addition, a resolution was carried at the Meeting to re-appoint KPMG LLP as the auditor of the Company and to authorize the Board to fix the auditor's remuneration. Detailed results of the votes are as follows: 1. Election of Directors 2. Appointment and Remuneration of Auditor Appointment of KPMG LLP as the auditor of the Company and authorizing the Company's board of directors to fix the remuneration of the auditor. About Optiva Inc. Optiva Inc. is a leading provider of mission-critical, cloud-native, agentic AI-powered revenue management software for the telecommunications industry. Its products are delivered globally on the private and public cloud. The Company's solutions help service providers maximize digital, 5G, IoT and emerging market opportunities to achieve business success. Established in 1999, Optiva Inc. is listed on the Toronto Stock Exchange (TSX:OPT). For more information, visit . For additional information, please contact:

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Business Upturn

time2 hours ago

  • Business Upturn

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store